Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-09-10 16:31:53 ET · period of report 2026-09-08 · accession 0000875320-26-000272 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-10 16:31 | 2026-09-08 | VRTX | van Grunsven Jasper | EVP, CP, NPPO | A - Grant | $0.00 | +8,682 | 8,682 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-08 | A | A | 8,682 | $0.00 | 8,682 | D | — | — | (F1) Restricted stock unit award that vests in installments beginning on 09/08/2027. |